All SGLT-2 inhibitors found promising for diabetes management in Indian settings: JAPI

Maharashtra: SGLT2 Inhibitors could be considered as an add-on to all antidiabetic agents currently used for diabetes management in the Indian setting, researchers from Maharashtra have reported. 

In their study, published in the Journal of the Association of Physicians of India, they found that all the four SGLT2 inhibitors (Canagliflozin, Empagliflozin, Dapagliflozin, or Remogliflozin) are effective in reducing fasting blood sugar (FBS), HbA1c, body weight, post-prandial blood sugar (PPBS), and both systolic and diastolic blood pressure. Therefore, SGLT2 inhibitors or gliflozins can be the best choice to start early in patients with inadequately controlled type 2 diabetes mellitus (T2DM) receiving triple-drug therapy. This helps in significant weight reduction and controlling all parameters of glycemia. 

For the management of type 2 diabetes, a handful of sodium-glucose co-transporter 2 (SGLT2) inhibitors are available in the Indian and global markets. However, there is a scarcity of head-to-head comparisons between different SGLT2 inhibitors. To fill this knowledge gap, Deepak Bhosle, Deogiri Diabetic Care Centre, Aurangabad, Maharashtra, India, and colleagues aimed to analyze the effect of different SGLT2 inhibitors on glycemic control and body weight in Indian patients with T2DM in a prospective, interventional, nonrandomized study.